Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C.

Caliskan Y, Yelken B, Ozkok A, Gorgulu N, Yazici H, Telci A, Yildiz A.

BMC Nephrol. 2012 Jul 7;13:56. doi: 10.1186/1471-2369-13-56.

2.

The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study.

Aydin Z, Gursu M, Karadag S, Uzun S, Sumnu A, Doventas Y, Ozturk S, Kazancioglu R.

Ren Fail. 2014 Sep;36(8):1253-7. doi: 10.3109/0886022X.2014.937663.

PMID:
25040737
3.

Does hepcidin affect erythropoiesis in hemodialysis patients?

Eleftheriadis T, Kartsios C, Liakopoulos V, Antoniadi G, Ditsa M, Papadopoulos C, Anifandis G, Skirta A, Markala D, Stefanidis I.

Acta Haematol. 2006;116(4):238-44.

PMID:
17119323
4.

How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.

Li XY, Chang JP, Su ZW, Li JH, Peng BS, Zhu SL, Cai AJ, Zhang J, Jiang Y.

Ther Apher Dial. 2010 Jun;14(3):308-14. doi: 10.1111/j.1744-9987.2009.00783.x.

PMID:
20609184
5.

Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.

Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A.

Am J Nephrol. 2008;28(1):115-21.

PMID:
17943020
7.

Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease.

Lee SH, Jeong SH, Park YS, Hwang JH, Kim JW, Kim N, Lee DH.

Korean J Hepatol. 2010 Sep;16(3):288-94. doi: 10.3350/kjhep.2010.16.3.288.

8.

Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients.

Hsu SP, Chiang CK, Chien CT, Hung KY.

Blood Purif. 2006;24(3):311-6.

PMID:
16479095
9.

Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C.

Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R.

World J Gastroenterol. 2010 Apr 14;16(14):1747-52.

10.

Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.

Costa E, Pereira BJ, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A.

Am J Nephrol. 2008;28(4):677-83. doi: 10.1159/000121478.

PMID:
18354252
11.

Serum prohepcidin levels in chronic inflammatory bowel diseases.

Nagy J, Lakner L, Poór VS, Pandur E, Mózsik G, Miseta A, Sipos K.

J Crohns Colitis. 2010 Dec;4(6):649-53. doi: 10.1016/j.crohns.2010.07.010.

PMID:
21122575
12.

Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women.

Huang X, Fung ET, Yip C, Zeleniuch-Jacquotte A.

Blood Cells Mol Dis. 2008 Nov-Dec;41(3):265-9. doi: 10.1016/j.bcmd.2008.06.009.

13.

Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients.

Lin TJ, Liao LY, Chou JM, Liu SO, Wang CK.

Hepatogastroenterology. 2009 Jul-Aug;56(93):1146-51.

PMID:
19760959
14.

[Serum prohepcidin and other iron metabolism parameters in healthy adults].

Zekanowska E, Boinska J, Kwapisz J, Kedziora-Kornatowska K, Porzych K, Ratajczak M.

Przegl Lek. 2011;68(2):82-6. Polish.

PMID:
21751515
15.

Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.

Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M.

Ren Fail. 2009;31(10):876-83. doi: 10.3109/08860220903216071.

PMID:
20030521
16.

Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.

van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators..

PLoS One. 2012;7(7):e39783. doi: 10.1371/journal.pone.0039783.

17.

Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment.

Emans ME, Braam B, Diepenbroek A, van der Putten K, Cramer MJ, Wielders JP, Swinkels DW, Doevendans PA, Gaillard CA.

Kidney Blood Press Res. 2012;36(1):344-54. doi: 10.1159/000343392.

18.

Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.

Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, Kohno S.

Med Sci Monit. 2008 Sep;14(9):CR431-7.

PMID:
18758412
19.

Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.

Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB.

Clin J Am Soc Nephrol. 2010 Jun;5(6):1010-4. doi: 10.2215/CJN.08161109.

20.

Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.

Malyszko J, Malyszko JS, Mysliwiec M.

Kidney Blood Press Res. 2009;32(4):235-8. doi: 10.1159/000235747.

Supplemental Content

Support Center